Home/Pipeline/NAMPT - Obesity

NAMPT - Obesity

Obesity

DiscoveryActive

Key Facts

Indication

Obesity

Phase

Discovery

Status

Active

Company

Remedy Plan Therapeutics

About Remedy Plan Therapeutics

Remedy Plan Therapeutics is pioneering a novel approach to NAMPT inhibition, a core metabolic enzyme implicated in over 20 diseases including cancer, autoimmune disorders, and obesity. Its proprietary drug screening platform has yielded RPT1G, a first-in-class clinical candidate with an unprecedented allosteric mechanism aimed at delivering efficacy without the severe toxicity of prior NAMPT inhibitors. The company is advancing RPT1G in oncology while leveraging its platform to discover new drugs for autoimmune and metabolic indications. With its lead program now in Phase 1, Remedy Plan is positioned to validate a new therapeutic paradigm for a high-value but historically intractable target.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Metabolic Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active